RegenCen's State of Menopause Care Report finds nearly two-thirds of women have felt dismissed by a healthcare provider — and most don't know federal guidance on hormone therapy changed last year ANN ARBOR, Mich. — September 9, 2026 — In November 2025, the U.S. Food and Drug Administration took the unusual step of stripping decades-old boxed warnings for cardiovascular disease, breast cancer and dementia from many hormone therapy products — one of the most significant shifts in menopause care policy